France is exploring coVID-19 treatment options based on antimalarial drugs

Sanofi Pharmaceuticals says it is ready to provide millions of dollars to the government to help treat 300,000 new coronavirus patients. In a limited study, tests using the antimalarial drug Plaquenil showed that 75 percent of COVID-19 patients had a six-day transition. While the results are encouraging, the government says further independent trials are needed to test them, rather than rush.

France is exploring coVID-19 treatment options based on antimalarial drugs

While people are home and taking frequent hand-washing measures to slow the spread of the epidemic, researchers need time to delve into the new coronavirus to understand the mechanism of action and develop treatment options.

Earlier, Australian doctors explained in a study how the immune system copes with the infection of the new coronavirus. In addition, laboratories around the world are working to develop vaccines.

What’s more, clinicians are experimenting with a variety of drug combinations to speed up patient recovery. An anti-flu drug called favipiravir, for example, used in Japan, offers a glimmer of hope for the first line.

Another striking finding is hydroxychloroquine (Plaquenil), which France is currently considering for future trials. Agence France-Presse reported that Sanofi is preparing to provide millions of drugs to the government to treat more than 300,000 COVID-19 patients.

A limited study conducted in Marseille partially confirms some of Plaquenil’s efficacy. Professor Didier Raoult treated 24 COVID-19 patients with the drug and found that 75% of cases can go to the shadow after six days.

Sanofi told AFP the company was preparing to work with French health authorities to confirm the drug’s effectiveness. But the French government says the first round of tests is under-supported by science and needs to be extended to a larger patient population.

An independent team of researchers will conduct new experiments, while others recommend caution until more research progresses.

After all, the drug, which can also be used to treat autoimmune diseases such as lupus and rheumatoid arthritis, may cause adverse reactions when used too much.

Earlier, amid some controversy, some experts suggested that French Health Minister Oliver Veran warn edgtos not to use ibuprofen and other NSAID to treat COVID-19 before gaining more evidence.

In addition, Sanofi is developing a vaccine against the new coronavirus and has created a fund to support other research at the Paris Public Hospital (AP-HP).